U.S. market Closed. Opens in 6 hours 4 minutes

DSGN | Design Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
RevenueN/AN/AN/A226.00834.00
Cost of Revenue537.00K466.00K129.00K5.00K1.65K
Gross Profit-537.00K-466.00K-129.00K-4.77K-820.00
Operating Expenses78.19M67.59M35.83M8.33M1.91M
Selling, General & Admin21.13M18.98M11.05M2.50M1.09M
Research & Development57.06M48.61M24.78M6.06M1.65M
Other Operating ExpensesN/A4.29M298.00K-226.00K-834.00K
Operating Income-78.19M-67.59M-35.83M-8.33M-1.91M
Other Expenses / Income11.33M4.29M298.00K50.00K-139.00K
Before Tax Income-66.86M-63.31M-35.53M-8.28M-2.05M
Income Tax Expenses-537.00K-4.69M-107.56K-201.30K-1.91K
Net Income-66.86M-58.62M-35.53M-8.28M-2.05M
Interest ExpensesN/A-4.69MN/AN/AN/A
Basic Shares Outstanding55.98M55.71M45.94M27.19M27.19M
Diluted Shares Outstanding55.98M55.71M45.94M27.19M27.19M
EBITDA-78.19M-67.59M-35.70M-8.32M-1.91M
EBITDA Margin0.00%0.00%0.00%-3,683,628.32%-228,776.98%
EBIT-67.40M-68.00M-35.64M-8.48M-2.05M
EBIT Margin0.00%0.00%0.00%-3,752,786.28%-245,672.42%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙